Author, Year	Location	Study Design	Model Type	Disease/Condition	Opinion Parameters	Opinion Solicitation Details	Other Sources Considered for Opinion Parameters
Aballéa, 200745	Brazil, France, Germany, Italy	CEA	Decision Analytic	Influenza Vaccination	Proportion currently eligible for vaccination reimbursement	NR	Data from other countries
Abernethy, 200346	US	Decision Analysis	Clinical Decision and Economic Analysis Model	Cancer	Probability that cancer pain patient would require intervention	Clinical experts	Published intervention rates
Amin, 200447	US	Decision Analysis	Markov Decision Analytic	Liver transplantation	Replantation; probability of spontaneous recovery following primary graft failure	Personal communication with an expert	None
Annemans, 201448	Belgium	CEA	Decision Analytic	Major Depressive Disorder	Difference in suicide risk post remission or relapse between treatment types; time to remission or therapy change; most commonly prescribed medications; validation of model structure and assumptions;	Experts were used to validate assumptions and provide inputs	Published literature
Banz, 20058	Europe (Switzerland)	CEA	Decision Analytic	Heart Failure	Adverse events; treatment utilization	Nine medical experts	Published literature
Banz, 200949	Switzerland	CEA	Dynamic Transition Decision Analytic	Varicella Vaccination	Coverage rate; relative susceptibility; risk of neurological complications; hospitalization from bacterial super infection, neurological complication, otitis media; death due to super infection, otitis media, or other complications; physician contacts in cases of infection; antiviral drug use; length of stay for severe complications;	Expert panel	Published literature
Beck, 198750	US	Decision Analysis and CEA	Decision Analytic	Symptomatic Bifascicular Block	Adverse events; treatment plans	NR	Published literature
Benneyan, 202151	US	Epidemiological Modeling	Differential Equation and Agent-Based Models	COVID-19	Cross exposure to COVID-19 between campus and community; proportion of the exposed who become infected; effects of reopening plans	NR	Published literature; grey literature
Bennison, 201652	UK	CEA	Economic model-Decision Analytic	Vitreomacular Traction and Macular hole	Treatment success	NR	None
Bernard, 201753	Singapore	CEA	Markov Cohort	Atopic Dermatitis	Treatment use; parent time lost	Three Singapore based clinicians who treat children with atopic dermatitis provided their opinion	Previous models, and the published literature
Bhanegaonkar, 201554	Malaysia	CEA	Markov	Atopic Dermatitis	Distribution of cases and probability of flares by severity and age group; clinical management resource use	Malaysian pediatricians with experience treat atopic dermatitis	Published literature
Bieri, 202055	Switzerland	Comparative Effectiveness	Discrete Event Simulation	Prostate Cancer	Time to start of treatment; time to end of treatment by receipt of radiotherapy; progression free interval;	Expert opinion was obtained from nephrologists with longstanding expertise in nephrology and/or fellowship trained uro-oncologists	Published literature
Boakye, 201256	US	Decision Analysis	Decision Analytic	Adjacent Segment Disease	Probability of adjacent segment disease in a patient with a previous asymptomatic degenerative disc	NR	Published literature
Bramley, 200357	New Zealand	CEA	Decision Analytic	Universal antenatal screening for HIV	HIV prevalence in New Zealand; clinical protocols for care of women with HIV	Infectious disease experts provided information.	None
Broekhuizen, 201858	The Netherlands	Multi-Criteria Decision Analysis	Decision Analytic	Lung Cancer Screening	Sensitivity and specificity, radiation burden attributes, and lower and upper bounds	Clinical expertise of two authors	Published literature
Buchanan, 201759	UK	CEA	Markov Model	Chronic Lymphocytic Leukaemia	Probability of undergoing refractory ofatumumab treatment by mutation type	Clinicians estimated the proportion of patients treated with ofatumumab that would be fit enough for a bone marrow transplant which was then converted to a 28-day transition probability.	None
Bullement, 201960	UK	CEA	Partitioned Survival Model	Metastatic Merkel Cell Carcinoma	Improvement in overall survival for avelumab, frequency of GP visits; adverse event disutilities	An advisory board and follow-up one-to-one consultations validated the model	None
Burd, 200261	US	Decision Analysis	Decision Analytic	Protective Anti-reflux Procedures in Neurologically Impaired Children	Postoperative outcomes	NR	Published Literature
Burg, 202162	The Netherlands	CEA	Decision Analytic Model	Endometrial Cancer	Percentage of patients with: treatment side effect symptomatic lymphocele and no lymph node metastasis; recurrence rate; radiotherapy induced toxicity rate; lymphedema rate; local recurrence rate; regional failure rate; mortality rate	Consulted two experts in the field	Published Literature
Burgette, 201863	US	CEA	Decision Tree	Childhood Dental Caries	Various (but not all) probabilities associated with treatment success by sedation method	Six-member panel with pediatric dentistry expertise	Published literature
Campbell, 199864	US	Epidemiological Modeling	Deterministic	Lyme Disease	Lyme disease cases; and people with unrecognized bites	Expert opinion of the authors	Unpublished data for select parameters
Cannon, 201865	Australia	CEA	Markov	Streptococcus Skin Infections	Proportions of outcomes attribute to Group A Streptococcus and disability weights	Infectious disease experts provided information	Published literature and local pathology studies
Castro-Jaramillo, 201266	England and Colombia	CEA	Markov	Pompe Disease	Life expectancy	NR	None
Chang, 202167	Taiwan	Cost Utility Analysis	Partitioned-Survival Model	Metastatic Merkel Cell Carcinoma	Treatment duration; incidence of adverse events	Three Taiwanese medical oncology experts were consulted.	Literature Review
Chiou, 200368	US	Economic Analysis	Markov	Female Contraception	Unspecified probability estimates	Expert opinion was used to derive estimates and verify accuracy of estimates	None
Chirikov, 201969	US	CEA	Markov	Multiple Sclerosis	Probability, disutility and duration of treatment related adverse events	NR	FDA warning labels
Cipriano, 200770	Canada	CEA	Decision Analytic	Newborn Screening	Incremental mortality of metabolic diseases; social and physical development by age	NR	Published literature
Crivellaro, 201971	US	Decision Analysis	Markov	Benign Prostatic Hyperplasia	State transition probabilities	NR	Results from a systematic review were used to adjust expert opinion using the Lagrangian approach
Das, 201372	UK	CEA	Markov	Advanced Breast Cancer	Treatment skipping, duration, costs, and proportion of patients per sequence	NR	Published Literature
de Rooij, 201473	The Netherlands	CEA	Decision Tree and Markov	Prostate Cancer Diagnosis	Probability of treatment with insignificant tumor	NR	None
Delgado, 200774	US	Decision Analysis	Markov Decision Analytic	LVAD Removal	Some probabilities (no specifics listed); health utilities	A range of cardiac transplant and surgical practitioners were interviewed	Literature reviews
Demarteau, 201275	Taiwan	CEA	Markov Model	HPV Vaccination	Seven screening and treatment related probabilities; proportions of nine HPV variants and cervical cancer	Local experts updated data for the Taiwanese setting	Published literature, country-specific databases
Dieleman, 202076	The Netherlands	CEA	Discrete Event Simulation	Cardiac Surgery	Probability of complicated cardiopulmonary bypass weaning by treatment; probability of surgery given complicated weaning by treatment type; probabilities of long-term cardiovascular events; costs	Two clinical experts were consulted	Published Literature
Dijkstra, 201777	The Netherlands	CEA	Decision Tree and Markov	Prostate Cancer Screening	Treatment probabilities	NR	Previous CEA on prostate cancer
Dornan, 201778	US	CEA	Markov Decision Analytic	Rotator Cuff Repair	Distribution of long-term complication and failure rates; and disutilities	Senior authors on the study	None
Druais, 201679	France	CEA	Markov	Schizophrenia	Therapeutic sequence; treatment choice; treatment interruption; adverse events; outpatient visits; minimums and maximums for sensitivity analyses	Advisory panels and questionnaires	Published literature
Duff, 200380	US, UK, Canada	CEA	Decision Analytic	Food Borne Illnesses	Efficacy of cleaning products; causes of food borne infections; costs of sequelae; utility estimates	Expert panel	Published literature and unpublished data
Ekaette, 200781	Canada	Value of Information	Monte Carlo Simulation	Cancer Staging	Comorbidities; staging; primary metastatic site assignment;	Two co-author experts	None
Enaoria, 201682	US	Epidemiological Modeling	Agent-Based Network Model	Measles	Behavioral inputs of the model	Personal communication with an expert	None
Fournier, 201383	Canada	Resource Utilization	Discrete Event Simulation	Neonatal Intensive Care Unit Capacity	NR	NR	NR
Gaidos, 200884	US	Decision Analysis	Decision Tree	Non-alcoholic Fatty Liver Disease	Probability of an insufficient biopsy sample; liver biopsy complications	NR	None
Garside, 200485	UK	CEA	Markov	Heavy Menstrual Bleeding	Wait time for hysterectomy; percentage of women receiving hysterectomy over repeat ablation	NR	Published literature
Gorelik, 202086	US	CEA	Decision Analytic	Sacroiliitis Diagnosis	Recovery following first line treatment; costs of complications; adverse event disutilities	NR	None
Guyat, 201787	UK	CEA	Parametric Survival Model	Cancer	Overall survival	NR	Published literature, SEER data, preliminary RCT data
Gyftopoulos, 201888	US	CEA	Decision Analytic	Adhesive Capsulitis	Probability of symptoms decreasing after treatment success or failure	Two senior physician authors (one orthopedic surgeon, one musculoskeletal radiologist)	None
Gyftopoulos, 201789	US	CEA	Decision Analytic	Symptomatic full-thickness supraspinatus tendon tears	Probabilities of going on to surgery after imaging after a false-positive imaging study, after a false-negative imaging study, and after a truepositive MRI study following a false-negative ultrasound examination.	Two shoulder and elbow fellowship-trained orthopedic surgeons	None
Hensen, 201090	Sweden	CEA	Discrete-event simulation	Schizophrenia	Treatment compliance and location	Three Swedish clinicians were interviewed	Published literature
Imperiale, 199591	US	Cost Analysis	Decision Analytic	Duodenal Ulcer	Probability of recurrence and re-endoscopy	NR	None
Iskedjian, 200892	Canada	CEA	Decision Analytic	Generalized Anxiety Disorder	Medication adherence switching and augmentation rates; resource use for follow-up	Clinical experts and physician questionnaire	None
Jin, 202093	UK	CEA	Decision Analytic	Schizophrenia	Treatment wait time; uptake of monitoring high risk individuals; medication use	Academic researchers, National Health Service practitioners, commissioners of mental health services and service users	None
Johal, 201394	UK	CEA	Markov	Non-metastatic Osteosarcoma	Adverse events; resource utilization; frequency of routine monitoring;	NR	Studies from the European context
John, 201795	India	CEA	Decision Analytic	Glaucoma	Glaucoma severity	NR	None
Karanicolas, 200796	Canada	CEA	Decision Analytic	Esophageal achalasia	Probability of recurrence; major and minor complication rates; adverse event rates	Two gastroenterologists and three thoracic surgeons	Literature review
Keshavarz, 201697	Iran	Cost Utility and Cost Effectiveness Analysis	Markov Microsimulatio n Model	HBeAg-Negative Chronic Hepatitis B	Disease states of patients and transition probabilities; costs; treatment effectiveness	NR	Published literature; patient self-report; local observations
Kruger, 199898	US	CEA	Decision Analytic	Arthritis	Treatment completion, treatment session number and duration	Opinion came from researchers and Arthritis Foundation staff	None
Kruyt, 202099	The Netherlands	CEA	Markov Model	Hearing Implants	Complications per-year; incidence of complications over time; skin overgrowth	Two clinical experts with bone-anchored hearing implant experience were consulted.	None
Kulkarni, 2007100	Canada	Decision Analysis	Decision Analytic	High-Risk T1G3 Bladder Cancer	Estimates of probabilities or utilities	Uro-oncologists	None
Larsen, 1992101	US	CEA	Decision Analytic	Sudden Cardiac Death	Clinical event rates and probabilities	NR	None
Leeftink, 2020102	The Netherlands	Risk Analysis	Monte Carlo Simulation	Post-Surgical Drug Adherence	NR	Clinical and simulation experts provided model inputs	NR
Leong, 2010103	The Netherlands	CEA	Markov	Idiopathic Overactive Bladder	Treatment effects and duration	A survey sent to 13 urologists	None
Little, 2007104	South Africa	Epidemiological Modeling	Deterministic State Transition	Vertical HIV infections	Efficacy of opportunistic infection treatments	NR	None
Locker, 2007105	US	CEA	Markov	Breast Cancer	Duration of risk of potentially fatal adverse events, resource utilization	Opinion from the Arimidex, Tamoxifen Alone or in Combination Trial steering committee	None
Lubinga, 2015106	Uganda	CEA	Decision Analytic	Postpartum Hemorrhage	Proportion of patients with access to emergency care	consultant obstetrician and gynecologist in Uganda	None
Lumie, 2016107	The Netherlands	CEA	Decision Analytic	Arthritis	Test characteristics and costs; utility values; frequency of tests	NR	Published literature; government health authority
Lundqvist, 2020108	Sweden	CEA	Decision Analytic Model	Prostate Cancer	Risks of adverse events; resource use	Expert opinion was elicited via questionnaires devised by the research group. The respondents were identified with help from the Regional Cancer Center South East. Two different questionnaires were devised and the questions were addressed to oncologists and urologists.	Published Literature
Magee, 2020109	UK	CEA	Markov Model	Gastric Antral Vascular Ectasia	Disease pathway; treatment clinical efficacy; probability of adverse events	Elicited via structured telephone interviews of four NHS consultant gastroenterologists.	None
Maklin, 2011110	Finland	CEA	Decision Tree and Markov	Bariatric Surgery	Proportions of surgical technique, patient characteristics; prevalence of diabetes and sleep apnoea; surgical mortality; reoperation rate	Bariatric surgeons	Hospital data; representative health survey data; published literature
Makris, 2003111	Canada	CEA	Clinical Decision Analytic	Dyspepsia	Estimates and ranges for the prevalence h. pylori; median length of time to treatment failure	Expert panel of gastroenterologists	None
Mandavia, 2020112	UK	CEA	Decision Analytic Model	Hearing Loss	Decision tree and state transition probabilities; utility scores; type of treatment used by severity of hearing loss; complication rates	Clinicians, audiologists, health economic modellers. industry representatives and patients were consulted.	Published scientific and grey literature
Mankowski, 2016113	Scotland	CEA	Decision Tree	Peripheral Neuropathic Pain	Efficacy of the final line of therapy	Expert panel included pain physicians (n = 3), pain nurses (n = 4), a senior academic (n = 1); and a general practitioner (n = 1)	None
Mansel, 2007114	UK	CEA	Markov	Breast Cancer	Duration of risk of adverse events; risk of hip fractures	Six practicing UK breast cancer specialists	Clinical trial data
Masucci, 2019115	Canada	CEA	Decision Analytic	Biliary Atresia	Time to first transplant; probability of second transplant	Clinical hepatology experts	None
Mavranezouli, 2020116	UK	CEA	Decision Analytic	Post-traumatic Stress Disorder	Annual risk of relapse; costs	Clinical academic, and health providers with service user and carer representatives with expertise and experience in the field of PTSD	Published literature and national databases
McCrone, 2009117	UK	CEA	Decision Analytic	Psychosis	Discharge to community mental health team	NR	None
Mnatzaganian, 2015118	Australia	CEA	Decision Analytic-Markov	Cobalamin Deficiency	NR	Co-authors and an external expert	Published evidence
Mohiuddin, 2015119	UK	CEA	Decision Analytic	Otitis Media with Effusion	Potential hearing gain after 12 months; utilities; costs	Three clinical experts	Published expert opinion
Moretti, 2018120	Canada	CEA	Decision Analytic	CYP2D6 Ultrarapid metabolizer phenotype	Probability of receiving codeine; probability of hospital admission	One expert was consulted	None
Najib, 2000121	US	CEA	Decision Analytic	Community-Acquired Pneumonia	NR	NR	Published literature
Nazir, 2015122	UK	CEA	Markov	Overactive Bladder	Final line therapy; number of consultations	Six clinical experts	None
Nietert, 2000123	US	Decision Analysis	Decision Analytic-Markov model	Ischemic stroke	State transition probabilities; adverse events; quality of life	Expert panel of clinicians	Published literature
Ondhia, 2019124	Canada	CEA	Three-state survival model	Non-Small Cell Lung Cancer	Duration of adverse events; utilities; subsequent therapies; resource utilization	Canadian clinical experts	None
Ophuis, 2018125	The Netherlands	CEA	Markov	Panic Disorder	Intervention uptake; Intervention costs	NR	Health economic guidelines
Panchmatia, 2016126	Sweden	CEA	Markov	Macular Degeneration	Monitoring frequency in clinical practice; ranges for sensitivity analyses	NR	Published literature for sensitivity analyses
Pitt, 2006127	UK	Cost Utility Analysis	Decision Analytic	Mild and Moderate Atopic Eczema	Transition probabilities	NR	None
Prosser, 2011128	US	CEA	Decision Analytic	H1N1	Incidence of hospitalizations for pneumonia or other respiratory conditions due to pH1N1 influenza per 100,000	NR	Published data
Rebenitsch, 2011129	US	Decision Analysis	Decision Analytic-Markov model	Keratoconus	Medical treatment regimens after surgery	NR	None
Richards, 2002130	US	CEA	Decision Analytic	Diverticulitis	Transition state probabilities, probabilities of clinical events	NR	Published literature
Rogers, 2008131	UK	CEA	Markov	High-grade Gliomas	Rate of health utility decline in progressive state	Three clinical experts	None
Scheckter, 2020132	US	CEA	Decision Tree	Partial Thickness Burns	Treatment effects of allografting; utilities	NR	NR
Scholte, 2019133	Netherlands	CEA	Decision Analytic- state-transition model	Vestibular Schwannoma	Treatment outcomes; costs of post-treatment care	Otolaryngology, radiology, and neurosurgery experts	None
Shamout, 2018134	Canada	Cost Utility Analysis	Decision Analytic-Markov model with Monte Carlo simulation	Post Prostatectomy Stress Urinary Incontinence	Annual Transition Probabilities; health-utilities	NR	Published literature
Shen, 2016135	China	CEA	Decision Analytic	Influenza-like Illness	Sensitivity and specificity of a rapid influenza diagnostic test	NR	Published literature
Shrestha, 2010136	US	Budget Impact Analysis	NR	Pediatric Vaccine Stockpile	Potential impacts of unvaccinated child by vaccine type	NR	Published literature
Simon, 2019137	UK	CEA	Decision Tree and Markov Model	Depression	Treatment effects and discontinuation; relapse rate; remission; costs	Interviews with practitioners (n=14) and online survey of primary care providers (n=50)	National databases
Smits, 2007138	The Netherlands	CEA	Decision Analytic	Major Depressive Disorder	Treatment outcomes by genotype; all sensitivity ranges	Several experts in psychopharmacology	Published literature
Stam, 2008139	Italy	CEA	Decision Analytic	Empiric Antifungal Treatment in Patients with Neutropenic Fever	Probability of ICU stay by treatment branch; length of ICU stay for patients; costs	Four clinical experts led by one of the coauthors	None
Stellato, 2019140	US	Budget Impact Analysis	Decision Analytic	Melanoma	Proportion of Stage III cases successfully resected; proportion of different treatments by year	NR	National databases; market research data
Stockdale, 2017141	UK	CEA	Decision Analytic	Tinnitus	Transition probabilities; costs; clinical pathways	Six researchers, four of whom were co-authors who through discussion formulated consensus on missing parameters	Survey of British Tinnitus Association, and published literature
Strand, 2016142	Ethiopia	CEA	Decision Analytic	Neuropsychiatric Disorders	Disease prevalence	Hospital and health department experts	Global Burden of Disease estimates
Tappenden, 2013143	UK	CEA	Decision Analytic - Bayesian Markov chain Monte Carlo methods	Colorectal Cancer	The probabilities that patients receive particular treatments	NR	Unpublished survey data
Teppakdee, 2002144	Thailand	CBA	Markov	Hepatitis A vaccination	NR	NR	Supplemented with published data when available
Tiwana, 2012145	US	CEA	Decision Analytic - Markov model	Newborn Screening	Event probabilities in screened and unscreened infants; costs related to false positive screen	NR	Published literature
Treur, 2012146	Spain	CEA	Discrete Event Simulation	Schizophrenia	Compliance rates; monitoring costs	NR	None
Udeh, 2008147	US	CEA	Decision Analytic	Adenoviral Conjunctivitis	NR	NR	Primary data sets; published literature
Verklejj, 2020148	Albania	CEA	Microsimulation	Neonatal Hearing	Screening participation rates; probability of treatment type; costs of special education and early family interventions;	Multiple expert meetings including sessions that update data from other countries to the Albanian context.	Data from other countries
Vodicka, 2020149	Philippines	CEA	Markov Model	Japanese Encephalitis	Probability of treatment for sequelae by severity; vaccine coverage; cost of vaccine delivery	In-country expert opinion in addition to key administrative and clinical personnel at the national and regional Departments of Health, facility-level and national laboratories, vaccine storage facilities, and the Western Pacific Regional Office of WHO.	None
Von Bargen, 2015150	US	Cost Utility Analysis	Decision Analytic	Stress Urinary Incontinence	Probability of expectant management success, utility value for pelvic floor muscle therapy	NR	None
Walzer, 2018151	UK	CEA	Decision Analytic-Markov	Venous Leg Ulcers	Transition probabilities for the different treatments	Clinician and wound nurse	None
Watkins, 2016152	Africa	CEA	Decision Analytic-Markov	Rheumatic Fever and Rheumatic Heart Disease	NR	NR	Historical Data
Wilson, 2007153	UK	CEA	NR	Lupus Nephritis	NR	NR	Systematic Reviews
Wirth, 2017154	Germany	CEA	Markov	Multidrug-Resistant Tuberculosis	Treatment algorithm; costs of adverse events	NR	Clinical guidelines and clinical study data
Yanagi, 2017155	Japan	CEA	Markov	Macular Degeneration	Treatment discontinuation; number of monitoring visits and maintenance injections	The authors and colleagues provided expert opinion	Published literature

US = United States, UK = United Kingdom, CEA = Cost-Effectiveness Analysis; NR = Not Reported